title: A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease.
abstract: The presence and the role of soluble gp130, the soluble form of a component of the interleukin (IL)-6 receptor complex, were investigated in inflammatory bowel disease. The serum concentrations of soluble gp130 were increased in ulcerative colitis (active disease, median, 93.5 ng/ml; interquartile range, 26-125 ng/ml; inactive disease, 81 ng/ml, 24.8-137.3 ng/ml) and to a lesser extent in Crohn's disease (active disease, 66 ng/ml, 44.4-87.6 ng/ml; inactive disease, 63 ng/ml, 43.5-82.5 ng/ml) compared to normal controls (43 ng/ml, 27-59 ng/ml). Paired analysis of serum samples showed a decrease of IL-6 and soluble IL-6 receptor concentrations in both diseases and an increase of soluble gp130 concentrations, especially in ulcerative colitis, just after the resolution of disease exacerbation. Size fractionation of the serum revealed that a part of the IL-6 co-eluted with soluble gp130 and soluble IL-6 receptor. The IL-6-induced proliferation of murine B9 hybridoma was enhanced by recombinant soluble IL-6 receptor, whereas the proliferation was inhibited by recombinant soluble gp130. These results indicate that soluble gp130 may function as a natural inhibitor of the IL-6 actions in inflammatory bowel disease.
authors.affiliation: Second Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan. ibd@med.kurume-u.ac.jp
authors.forename: K
authors.initials: K
authors.lastname: Mitsuyama
authors.forename: N
authors.initials: N
authors.lastname: Tomiyasu
authors.forename: A
authors.initials: A
authors.lastname: Suzuki
authors.forename: K
authors.initials: K
authors.lastname: Takaki
authors.forename: H
authors.initials: H
authors.lastname: Takedatsu
authors.forename: J
authors.initials: J
authors.lastname: Masuda
authors.forename: H
authors.initials: H
authors.lastname: Yamasaki
authors.forename: S
authors.initials: S
authors.lastname: Matsumoto
authors.forename: O
authors.initials: O
authors.lastname: Tsuruta
authors.forename: A
authors.initials: A
authors.lastname: Toyonaga
authors.forename: M
authors.initials: M
authors.lastname: Sata
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D002850:Chromatography, Gel; D003092:Colitis / Q000276:immunology; D003093:Colitis, Ulcerative / Q000276:immunology; D003424:Crohn Disease / Q000276:immunology; D050822:Cytokine Receptor gp130 / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D006801:Humans; D006825:Hybridomas; D015212:Inflammatory Bowel Diseases / Q000276:immunology*; D015850:Interleukin-6 / Q000032:analysis / Q000097:blood*; D008297:Male; D008875:Middle Aged; D019947:Receptors, Interleukin-6 / Q000097:blood; D018709:Statistics, Nonparametric
chemical_list: D015850:Interleukin-6; D019947:Receptors, Interleukin-6; D050822:Cytokine Receptor gp130